Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

@article{Jeppesen2013QualityOL,
  title={Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.},
  author={Palle B Jeppesen and Marek Pertkiewicz and Alastair Forbes and L Pironi and Simon M. Gabe and Francisca Joly and Bernard Messing and Susanne Loth and Nader N. Youssef and Hartmut Heinze and Peter Bergh{\"o}fer},
  journal={Clinical nutrition},
  year={2013},
  volume={32 5},
  pages={713-21}
}
BACKGROUND & AIMS Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…